



# The impact of plateletcrit on the diagnosis and management of gestational diabetes mellitus

Atilla Karateke<sup>a,\*</sup>, Raziye Keskin<sup>a</sup>

<sup>a</sup>Private Reyhanlı MMT Amerikan Hospital, Department of Gynecology and Obstetrics, Hatay, Türkiye

## ARTICLE INFO

### Keywords:

Blood count  
Gestational diabetes mellitus  
Plateletcrit  
Mean platelet volume  
Platelet

Received: Aug 01, 2024

Accepted: Oct 09, 2024

Available Online: 25.10.2024

DOI:

[10.5455/annalsmedres.2024.08.160](https://doi.org/10.5455/annalsmedres.2024.08.160)

## Abstract

**Aim:** Gestational diabetes mellitus (GDM) is a condition that can cause serious maternal and fetal complications. Platelets are one of the cells that play an important role in inflammation in our body. In this study, we aimed to investigate whether there is a relationship between platelet values obtained by a simple blood count and GDM.

**Materials and Methods:** Two groups consisting of 60 individuals with GDM and 250 healthy populations were created. Demographic characteristics, the sugar loading test results performed between 24th-28th weeks and simple complete blood count results including platelets, plateletcrit (PCT), platelet distribution width (PDW), and mean platelet volume (MPV) were analyzed with SPSS.

**Results:** When comparing the ages, BMI, average blood pressure, heights, and gestational weeks of both groups, there was no any significant differences ( $p>0.05$ ). In terms of the hemoglobin, platelet, and white blood cell counts, there wasn't any significant differences between the two groups ( $p>0.05$ ). MPV, PDW and PCT values were significantly increased in patients with GDM compared to healthy pregnant women ( $p<0.02$ ,  $p<0.009$ , and  $p<0.001$ , respectively). Specifically, there was a significant positive correlation was found between PCT and the 1st hour glucose level ( $r: 0.585$ ,  $p=0.001$ ).

**Conclusion:** We predict that a simple blood count (especially MPV, PDW and PCT values) performed during the first routine visit of pregnant women may be useful in predicting the risk of GDM.



Copyright © 2024 The author(s) - Available online at [www.annalsmedres.org](http://www.annalsmedres.org). This is an Open Access article distributed under the terms of Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

## Introduction

Gestational diabetes mellitus (GDM) is a medical condition that frequently occurs during pregnancy and can cause serious complications for both the mother and the fetus [1]. The prevalence of gestational diabetes is seen between 1% and 15% of pregnancies worldwide. Studies conducted in our country show that the prevalence of GDM varies between 3.0% and 28.0% [2]. Over the past few decades, the frequency of GDM has increased in the same trend as obesity and type 2 diabetes mellitus. The increase in GDM prevalence is likely to continue as obesity is on the rise globally in women [3].

Gestational DM causes short- and long-term complications for both mother and fetus. The most significant of these include preeclampsia, miscarriage, macrosomia, and consequently birth trauma, among others [4-6].

It has been reported that hormones such as growth hormone, progesterone, lactogen, and cortisol, which are secreted from the placenta during pregnancy, increase insulin

resistance and, along with underlying genetic predisposition, lead to GDM [7, 8]. Placental lactogen hormone, which increases especially during pregnancy, increases free fatty acids by increasing lipolysis. With these increased free fatty acids, insulin resistance also increases. High levels of insulin resistance also further accelerate the severity of inflammation. It is thought that the increased release of pro-inflammatory cytokines, including TNF- $\alpha$ , IL-6, and interleukin-1 (IL-1), in subchronic inflammation may contribute to the development of GDM [9-11].

Subchronic inflammation can lead to vascular damage and dysfunction over time, thereby impairing platelet functions. Since platelets are the first cells to respond to vascular damage, they are among the first to experience functional loss. As a first reaction, platelet functions may be impaired as a result of damage and loss of function in the vessels as a result of the progression of subclinical inflammation [12].

The best indicators representing platelet functions in complete blood count are plateletcrit (PCT), mean platelet volume (MPV), and platelet distribution width (PDW) parameters [11,12]. Studies in the literature have shown

\*Corresponding author:

Email address: [drkarateke@gmail.com](mailto:drkarateke@gmail.com) (Atilla Karateke)

that these parameters increase in diabetes, cardiovascular diseases, preeclampsia-eclampsia and fatty liver disease [13-15].

In this study, the relationship between MPV, PDW, and PCT levels and GDM in patients diagnosed with GDM was evaluated.

### Materials and Methods

#### Patient population

In this retrospectively designed study, laboratory values of pregnant women diagnosed with GDM and healthy pregnant women who attended outpatient clinic appointments at Hatay Private Reyhanlı MMT American Hospital Gynecology and Obstetrics Clinic between January 2022 and February 2024 were examined. According to the criteria of the International Association of Diabetes and Pregnancy Study Group (IADPSG), fasting blood glucose (FBG) is first measured on an empty stomach in the morning, followed by blood glucose levels at the 1<sup>st</sup> and 2<sup>nd</sup> hours after administering a 75 g glucose solution.

Accordingly, a diagnosis of GDM is made if two or three of the following values are elevated: FBG  $\geq 92$  mg/dl, 1<sup>st</sup> hour  $\geq 180$  mg/dl, 2<sup>nd</sup> hour  $\geq 153$  mg/dl. This test was performed to the all patients at 24-28 weeks of pregnancy. Also, complete blood count was taken at the 24-28 weeks of pregnancy.

Parameters within the complete blood count, including platelets, MPV (Mean Platelet Volume), PDW (Platelet Distribution Width), and PCT (Plateletcrit), were automatically counted using the Coulter LH 780 Hematology Analyzer device.

The study was divided into two groups. The first group included 250 healthy pregnant women, while the second group comprised 60 patients diagnosed with GDM. The inclusion criteria of the study were as follows having a pregnancy of 24-28 weeks according to the last menstrual period, Body Mass Index (BMI) of 18.5-29.9 before pregnancy, not using cigarettes, alcohol or drugs, not having a threat of miscarriage during pregnancy. The exclusion criteria for the study included a prior diagnosis of diabetes mellitus, the presence of preeclampsia, chronic inflammatory conditions, hemoglobinopathy, and autoimmune diseases.

Data on the ages, average blood pressure, height and weight, 75 g OGTT (Oral Glucose Tolerance Test) results, complete blood count, and BMI of all the pregnant women examined in the study were extracted from the hospital's archive system.

Our study was approved by the Ethics Committee of Adana City Education and Research Hospital (30.05.2024-1/2).

#### Statistical analysis

Kolmogorov Smirnov test was used to check the suitability of continuous variables for normal distribution. Student's t test was used to compare variables with normal distribution between 2 independent groups, and Mann Whitney U Test was used for variables with non-normal distribution. The results are presented as mean  $\pm$  standard deviation

(SD). Pearson chi-square / Fisher Exact Test were used in the analysis of nominal variables. Correlations were assessed using Spearman test. For statistical analyses, SPSS software (version 25.0, IBM, NY, USA) was performed. For  $p < 0.05$ , the results were considered statistically significant.

### Results

When comparing the ages, BMI, average blood pressure, heights, and gestational weeks of both groups, there were no any significant differences (Table 1).

In terms of the hemoglobin, platelet, and white blood cell counts, there weren't any significant differences between the two groups (Table 2).

MPV, PDW and PCT values were significantly increased in patients with GDM compared to healthy pregnant

**Table 1.** Comparing baseline characteristics of the healthy pregnant women (group 1) with diagnosed gestational diabetes mellitus pregnant women (group 2).

Variables	Group 1 (n=250) (mean $\pm$ SD)	Group 2 (n=60) (mean $\pm$ SD)	p value
Maternal age (year)	27.3 $\pm$ 3.42	28.5 $\pm$ 6.3	NS
Weight (kg)	70.7 $\pm$ 7.4	73.2 $\pm$ 5.1	NS
Height (cm)	161.3 $\pm$ 4.3	163.4 $\pm$ 3.2	NS
Body Mass Index (BMI)	25.9 $\pm$ 5.1	27.1 $\pm$ 2.5	NS
Systolic Blood Pressure (mmHg)	113 $\pm$ 11	118 $\pm$ 9	NS
Diastolik Blood Pressure (mmHg)	81 $\pm$ 5	79 $\pm$ 10	NS
Gestastional week (w/d)	26.3 $\pm$ 3	27.1 $\pm$ 2	NS

NS; non-significant ( $p > 0.05$ ).

**Table 2.** Comparison of hemoglobin, platelet, and white blood cell counts in groups.


Variables	Group 1 (n=250) (mean $\pm$ SD)	Group 2 (n=60) (mean $\pm$ SD)	p value
White Blood Cell ( $\times 10^3 \mu\text{L mm}^3$ )	11.3 $\pm$ 0.1	10.7 $\pm$ 2.2	NS
Hemoglobin (mg/dl)	10.5 $\pm$ 1.3	10.9 $\pm$ 1.6	NS
Platelet ( $10^3 / \text{mm}^3$ )	210 $\pm$ 25	223 $\pm$ 32	NS

NS; non-significant ( $p > 0.05$ ).


**Table 3.** Comparing the healthy pregnant women (group 1) with diagnosed gestational diabetes mellitus pregnant women (group 2).

Variables	Group 1 (n=250) (mean $\pm$ SD)	Group 2 (n=60) (mean $\pm$ SD)	p value
MPV (fl)	9.1 $\pm$ 0.9	9.8 $\pm$ 0.3	<0.02
PDW (%)	16.8 $\pm$ 1.9	18.5 $\pm$ 1.8	<0.009
PCT (%)	0.19 $\pm$ 0.3	0.21 $\pm$ 0.3	<0.001

MPV: Mean Platelet Volume, PDW: Platelet Distribution Width, PCT: Plateletcrit.



**Figure 1.** Correlation analysis between 60-minute glucose level and PCT value.



**Figure 2.** Correlation analysis between 120-minute glucose level and PDW value.

women ( $p < 0.02$ ,  $p < 0.009$ , and  $p < 0.001$ , respectively) (Table 3).

Specifically, there was a significant positive correlation was found between PCT and the 60-minute glucose level ( $r: 0.585$ ,  $p=0.001$ ) (Figure 1). In addition, we found poor positive correlation between 120-minute glucose level and PDW ( $r:0.498$ ,  $p: 0.009$ ) (Figure 2).

**Discussion**

In our study, it was determined that MPV, PDW, and PCT showed significant increases in patients diagnosed with GDM in the second trimester compared to the normal population. There were not any previous studies have reported a positive correlation between PCT and the 1-hour glucose level. In our study, we found a significant positive correlation between PCT and the 1-hour glucose level and we think that this connection could be a significant indicator in GDM.

It has been reported that the inflammatory process is as influential as hormones secreted from the placenta in the emergence of GDM [16, 17] Particularly during pregnancy, increased cytokines such as  $TNF-\alpha$ , IL-6, and C-reactive protein (CRP) are the main causes of subchronic inflammation, leading to vascular damage [18, 19]. When this vascular damage begins to develop, one of the first responding cells is platelets.

Several studies have shown that values such as MPV, PDW, and PCT, which indicate platelet function, increase especially during inflammation [20, 21]. It is now well known that MPV increases in systemic conditions such as cardiovascular disease and preeclampsia [22, 23].

Similarly, there are publications suggesting that MPV increases in patients with GDM. In their studies, Liu et al. and Wei et al. demonstrated a significant increase in MPV in patients with GDM compared to other healthy populations [24, 25]. Our study also found that MPV significantly increased in patients with GDM.

Moreover, PDW indicates morphological changes in platelets. If there is an increase in platelet activation, morphological changes begin, resulting in increased PDW values. This increase usually occurs due to inflammation. Xiang et al. reported a significant increase in PDW in their study of 96 GDM patients and 95 healthy individuals [26]. In our study, there was a significant increase in PDW in patients with GDM.

PCT, obtained by dividing the platelet volume by the platelet count, is considered an analog of hematocrit for platelets. It is known that the value of PCT in inflammation is much more significant and informative than platelet count, MPV, and PDW [27]. Şahbaz et al. revealed a more significant increase in PCT in GDM patients compared to other platelet markers [28]. In our study, there was a significant increase in PCT in patients with GDM.

*Limitations*

Our study has some limitations. The most important limitation of this article is its retrospective nature. Additionally, the small number of GDM patients and the single-center study are significant limitations. However, the strengths of our study there was not any previous studies have reported a positive correlation between PCT and the 1-hour glucose level. In our study, we found a significant positive correlation between PCT and the 1-hour glucose level and we think that this connection could be a significant indicator in GDM.

**Conclusion**

The results of this study indicate that platelet markers play an important role in the diagnosis of GDM. However, more comprehensive studies are needed to obtain more definitive data. Furthermore, increased MPV, PDW, and PCT values in a simple blood count during the initial visit of pregnant women should prompt consideration of potential GDM. In such cases, a thorough anamnesis should be taken from the patients, and risk factors should be carefully questioned.

*Informed consent*

Because the study was designed retrospectively, no written informed consent form was obtained from patients.

*Conflicts of interest*

None declared.

*Financial disclosure*

None.

### Ethical approval

Consent was obtained by all participants in this study. The study was initiated after the approval of Adana City Training and Research Hospital Ethics Committee (Approval date and No: 30/05/2024 / 1/2).

### Author contributions

A.K., R.K.: Conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published. Agreement to be accountable for all aspects of the work in ensuring that question related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

### References

1. Sweeting A, Hannah W, Backman H, Catalano P, Feghali M, Herman WH, et al. Epidemiology and management of gestational diabetes. *Lancet*. 2024;404(10448):175-92.
2. Melchior H, Kurch-Bek D, Mund M. The Prevalence of Gestational Diabetes. *Dtsch Arztebl Int*. 2017;114(24):412-18.
3. Ramezani Tehrani F, Sheidaei A, Rahmati M, Farzadfar F, Noroozadeh M, Hosseinpanah F, et al. Various screening and diagnosis approaches for gestational diabetes mellitus and adverse pregnancy outcomes: a secondary analysis of a randomized non-inferiority field trial. *BMJ Open Diabetes Res Care*. 2023;11(6).
4. Yang J, Song Y, Gaskins AJ, Li LJ, Huang Z, Eriksson JG, et al. Mediterranean diet and female reproductive health over lifespan: a systematic review and meta-analysis. *Am J Obstet Gynecol*. 2023;229(6):617-31.
5. Factor PA, Corpuz H. The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis. *J ASEAN Fed Endocr Soc*. 2023;38(2):102-12.
6. Ringholm L, Norgaard SK, Rytter A, Damm P, Mathiesen ER. Dietary Advice to Support Glycaemic Control and Weight Management in Women with Type 1 Diabetes during Pregnancy and Breastfeeding. *Nutrients*. 2022;14(22).
7. Hill M, Parizek A, Simjak P, Koucky M, Anderlova K, Krejci H, et al. Steroids, steroid associated substances and gestational diabetes mellitus. *Physiol Res*. 2021;70(Suppl4):S617-S34.
8. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. *Obstet Gynecol*. 2018;131(2):e49-e64.
9. Costa MA. The endocrine function of human placenta: an overview. *Reprod Biomed Online*. 2016;32(1):14-43.
10. Guevara-Ramirez P, Paz-Cruz E, Cadena-Ullauri S, Ruiz-Pozo VA, Tamayo-Trujillo R, Felix ML, et al. Molecular pathways and nutrigenomic review of insulin resistance development in gestational diabetes mellitus. *Front Nutr*. 2023;10:1228703.
11. Liu G, Geng J, Jin R, Zhang N, Mei L. The Clinical Significance Of Complete Blood Count, Neutrophil-To-Lymphocyte Ratio, And Monocyte-To-Lymphocyte Ratio In Gestational Diabetes Mellitus. *Acta Endocrinologica (Bucharest)*. 2023;19(4):441.
12. Duran-Bertran J, Rusu EC, Barrientos-Riosalido A, Bertran L, Mahmoudian R, Aguilar C, et al. Platelet-associated biomarkers in nonalcoholic steatohepatitis: Insights from a female cohort with obesity. *Eur J Clin Invest*. 2024;54(3):e14123.
13. Bawore SG, Adissu W, Niguse B, Larebo YM, Ermolo NA, Gedefaw L. A pattern of platelet indices as a potential marker for prediction of pre-eclampsia among pregnant women attending a Tertiary Hospital, Ethiopia: A case-control study. *PLoS One*. 2021;16(11):e0259543.
14. Lin S, Zhang L, Shen S, Wei D, Lu J, Chen X, et al. Platelet parameters and risk of hypertension disorders of pregnancy: a propensity score adjusted analysis. *Platelets*. 2022;33(4):543-50.
15. Becirovic E, Ljuca K, Becirovic M, Ljuca N, Bajric M, Brkic A, et al. Prognostic value of a decrease in mean platelet volume, platelet distribution width, and platelet-large cell ratio for major adverse cardiovascular events after myocardial infarction without ST-segment elevation: An observational study. *Biomol Biomed*. 2023;23(5):866-72.
16. Desoye G, Cervar-Zivkovic M. Diabetes Mellitus, Obesity, and the Placenta. *Obstet Gynecol Clin North Am*. 2020;47(1):65-79.
17. Bedell S, Hutson J, de Vrijer B, Eastabrook G. Effects of Maternal Obesity and Gestational Diabetes Mellitus on the Placenta: Current Knowledge and Targets for Therapeutic Interventions. *Curr Vasc Pharmacol*. 2021;19(2):176-92.
18. Artym J, Zimecki M, Kruzel ML. Lactoferrin for Prevention and Treatment of Anemia and Inflammation in Pregnant Women: A Comprehensive Review. *Biomedicine*. 2021;9(8)
19. Baki Yildirim S, Bezirganoglu Altuntas N, Bayoglu Tekin Y. Monocyte-to-lymphocyte ratio in the early second trimester is a predictor of gestational diabetes mellitus. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2024;37(1):2371979.
20. Hlapcic I, Somborac-Bacura A, Popovic-Grle S, Vukic Dugac A, Rogic D, Rako I, et al. Platelet indices in stable chronic obstructive pulmonary disease - association with inflammatory markers, comorbidities and therapy. *Biochem Med (Zagreb)*. 2020;30(1):010701.
21. Llewellyn EA, Todd JM, Sharkey LC, Rendahl A. A pilot study evaluating the prognostic utility of platelet indices in dogs with septic peritonitis. *J Vet Emerg Crit Care (San Antonio)*. 2017;27(5):569-78.
22. Ye D, Li S, Ding Y, Ma Z, He R. Clinical value of mean platelet volume in predicting and diagnosing pre-eclampsia: a systematic review and meta-analysis. *Front Cardiovasc Med*. 2023;10:1251304.
23. Bellos I, Fitrou G, Pergialiotis V, Papantoniou N, Daskalakis G. Mean platelet volume values in preeclampsia: A systematic review and meta-analysis. *Pregnancy Hypertens*. 2018;13:174-80.
24. Liu G, Geng J, Jin R, Zhang N, Mei L. The Clinical Significance of Complete Blood Count, Neutrophil-to-Lymphocyte Ratio, and Monocyte-to-Lymphocyte Ratio in Gestational Diabetes Mellitus. *Acta Endocrinol (Buchar)*. 2023;19(4):441-46.
25. Wei Y, Lin Y, Huang L, Wang C, Li R. Association between mean platelet volume and the risk of type 2 diabetes mellitus among women with history of gestational diabetes mellitus. *BMC Endocr Disord*. 2024;24(1):1-10.
26. Xiang LL, Chen C, Wang QY, Zhu YT, Chen YJ, Zeng Y. Impact of inflammatory factors, hemoglobin A1c, and platelet parameters in gestational diabetes mellitus. *Arch Gynecol Obstet*. 2023;307(2):439-46.
27. Coskun ME, Alidris A, Temel MT, Akbayram S, Hizli S. Plateletcrit: A possible biomarker of inflammation in hepatitis A infection. *Niger J Clin Pract*. 2019;22(5):727-30.
28. Sahbaz A, Cicekler H, Aynioglu O, Isik H, Ozmen U. Comparison of the predictive value of plateletcrit with various other blood parameters in gestational diabetes development. *J Obstet Gynaecol*. 2016;36(5):589-93.